

Jeffrey W Keillor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6287754/publications.pdf>

Version: 2024-02-01

92
papers

3,073
citations

126907

33
h-index

189892

50
g-index

95
all docs

95
docs citations

95
times ranked

2977
citing authors

#	ARTICLE	IF	CITATIONS
1	Sulforaphane covalently interacts with the transglutaminase 2 cancer maintenance protein to alter its structure and suppress its activity. <i>Molecular Carcinogenesis</i> , 2022, 61, 19-32.	2.7	11
2	Dysregulation of Transglutaminase type 2 through GATA3 defines aggressiveness and Doxorubicin sensitivity in breast cancer. <i>International Journal of Biological Sciences</i> , 2022, 18, 1-14.	6.4	6
3	Structure-activity relationships of hydrophobic alkyl acrylamides as tissue transglutaminase inhibitors. <i>RSC Medicinal Chemistry</i> , 2022, 13, 413-428.	3.9	7
4	Structure-activity relationships of N-terminal variants of peptidomimetic tissue transglutaminase inhibitors. <i>European Journal of Medicinal Chemistry</i> , 2022, 232, 114172.	5.5	12
5	Transglutaminase 2 Maintains Hepatocyte Growth Factor Signaling to Enhance the Cancer Cell Phenotype. <i>Molecular Cancer Research</i> , 2021, 19, 2026-2035.	3.4	6
6	Transglutaminase 2 as a therapeutic target for neurological conditions. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 721-731.	3.4	10
7	Deletion or Inhibition of Astrocytic Transglutaminase 2 Promotes Functional Recovery after Spinal Cord Injury. <i>Cells</i> , 2021, 10, 2942.	4.1	7
8	The Motility and Mesenchymal Features of Breast Cancer Cells Correlate with the Levels and Intracellular Localization of Transglutaminase Type 2. <i>Cells</i> , 2021, 10, 3059.	4.1	8
9	Infection-driven activation of transglutaminase 2 boosts glucose uptake and hexosamine biosynthesis in epithelial cells. <i>EMBO Journal</i> , 2020, 39, e102166.	7.8	12
10	Benefits of Combined All-Trans Retinoic Acid and Arsenic Trioxide Treatment of Acute Promyelocytic Leukemia Cells and Further Enhancement by Inhibition of Atypically Expressed Transglutaminase 2. <i>Cancers</i> , 2020, 12, 648.	3.7	9
11	Site-Specific Fluorogenic Protein Labelling Agent for Bioconjugation. <i>Biomolecules</i> , 2020, 10, 369.	4.0	6
12	A Precision Strategy to Cure Renal Cell Carcinoma by Targeting Transglutaminase 2. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2493.	4.1	5
13	Transglutaminase 2 programs differentiating acute promyelocytic leukemia cells in all-trans retinoic acid treatment to inflammatory stage through NF- κ B activation. <i>Haematologica</i> , 2019, 104, 505-515.	3.5	21
14	Designing Dual Transglutaminase-2/Histone Deacetylase Inhibitors Effective at Halting Neuronal Death. <i>ChemMedChem</i> , 2018, 13, 227-230.	3.2	13
15	Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formation. <i>Oncotarget</i> , 2018, 9, 34495-34505.	1.8	33
16	Antimicrobial peptide LL-37 and its truncated forms, GI-20 and GF-17, exert spermicidal effects and microbicidal activity against <i>Neisseria gonorrhoeae</i> . <i>Human Reproduction</i> , 2018, 33, 2175-2183.	0.9	14
17	Mechanisms of Alkyl and Aryl Thiol Addition to <i>N</i> -Methylmaleimide. <i>Journal of Organic Chemistry</i> , 2018, 83, 11674-11685.	3.2	14
18	A Green BODIPY-Based, Super-Fluorogenic, Protein-Specific Labelling Agent. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 12390-12394.	13.8	24

#	ARTICLE	IF	CITATIONS
19	Rational design of a highly reactive dicysteine peptide tag for fluorogenic protein labelling. <i>Organic and Biomolecular Chemistry</i> , 2018, 16, 6332-6340.	2.8	5
20	A Green BODIPY-Based, Super-Fluorogenic, Protein-Specific Labelling Agent. <i>Angewandte Chemie</i> , 2018, 130, 12570-12574.	2.0	12
21	Design of a glutamine substrate tag enabling protein labelling mediated by <i>Bacillus subtilis</i> transglutaminase. <i>PLoS ONE</i> , 2018, 13, e0197956.	2.5	12
22	Inhibition or ablation of transglutaminase 2 impairs astrocyte migration. <i>Biochemical and Biophysical Research Communications</i> , 2017, 482, 942-947.	2.1	12
23	Development of new scaffolds as reversible tissue transglutaminase inhibitors, with improved potency or resistance to glutathione addition. <i>MedChemComm</i> , 2017, 8, 338-345.	3.4	9
24	Transglutaminase 2 modulation of NF- κ B signaling in astrocytes is independent of its ability to mediate astrocytic viability in ischemic injury. <i>Brain Research</i> , 2017, 1668, 1-11.	2.2	20
25	Structure-Activity Relationships of Potent, Targeted Covalent Inhibitors That Abolish Both the Transamidation and GTP Binding Activities of Human Tissue Transglutaminase. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 7910-7927.	6.4	41
26	Hydroxy-substituted trans -cinnamoyl derivatives as multifunctional tools in the context of Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2017, 139, 378-389.	5.5	21
27	The complex role of transglutaminase 2 in glioblastoma proliferation. <i>Neuro-Oncology</i> , 2016, 19, now157.	1.2	13
28	Simultaneous analysis of enzyme structure and activity by kinetic capillary electrophoresis-MS. <i>Nature Chemical Biology</i> , 2016, 12, 918-922.	8.0	37
29	Transglutaminase Interaction with α 6 β 4-Integrin Stimulates YAP1-Dependent Np63 \pm Stabilization and Leads to Enhanced Cancer Stem Cell Survival and Tumor Formation. <i>Cancer Research</i> , 2016, 76, 7265-7276.	0.9	65
30	Transglutaminase inhibitors: a patent review. <i>Expert Opinion on Therapeutic Patents</i> , 2016, 26, 49-63.	5.0	38
31	Specificity of transglutaminase-catalyzed peptide synthesis. <i>Journal of Molecular Catalysis B: Enzymatic</i> , 2016, 123, 53-61.	1.8	2
32	Inhibition of Transglutaminase. , 2015, , 347-372.		1
33	Transglutaminase Is Required for Epidermal Squamous Cell Carcinoma Stem Cell Survival. <i>Molecular Cancer Research</i> , 2015, 13, 1083-1094.	3.4	50
34	Quantitative Analysis of the Efficacy and Potency of Novel Small Molecule Ice Recrystallization Inhibitors. <i>Crystal Growth and Design</i> , 2015, 15, 5034-5039.	3.0	17
35	Ring Substituent Effects on the Thiol Addition and Hydrolysis Reactions of <i>N</i> -Arylmaleimides. <i>Journal of Organic Chemistry</i> , 2015, 80, 12182-12192.	3.2	18
36	Inhibitors of tissue transglutaminase. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 32-40.	8.7	88

#	ARTICLE	IF	CITATIONS
37	Fluorogenic protein labelling: a review of photophysical quench mechanisms and principles of fluorogen design. <i>Canadian Journal of Chemistry</i> , 2015, 93, 389-398.	1.1	34
38	Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition. <i>Oncotarget</i> , 2015, 6, 20525-20539.	1.8	50
39	Acyl transfer mechanisms of tissue transglutaminase. <i>Bioorganic Chemistry</i> , 2014, 57, 186-197.	4.1	69
40	Coumarin-Based Fluorogenic Probes for No-Wash Protein Labeling. <i>Angewandte Chemie - International Edition</i> , 2014, 53, 13785-13788.	13.8	73
41	Microbial transglutaminase displays broad acyl-acceptor substrate specificity. <i>Applied Microbiology and Biotechnology</i> , 2014, 98, 219-230.	3.6	75
42	Site-specific protein labelling and immobilization mediated by microbial transglutaminase. <i>Chemical Communications</i> , 2014, 50, 6604-6606.	4.1	39
43	Transglutaminase and Polyamination of Tubulin: Posttranslational Modification for Stabilizing Axonal Microtubules. <i>Neuron</i> , 2013, 78, 109-123.	8.1	167
44	Continuous enzyme-coupled assay for microbial transglutaminase activity. <i>Analytical Biochemistry</i> , 2013, 441, 169-173.	2.4	23
45	Expression, purification and kinetic characterisation of human tissue transglutaminase. <i>Protein Expression and Purification</i> , 2013, 87, 41-46.	1.3	17
46	Site-specific protein propargylation using tissue transglutaminase. <i>Organic and Biomolecular Chemistry</i> , 2012, 10, 5258.	2.8	22
47	Real-Time Monitoring of Protein Conformational Dynamics in Solution Using Kinetic Capillary Electrophoresis. <i>Angewandte Chemie - International Edition</i> , 2012, 51, 12464-12468.	13.8	35
48	Using FLIM-FRET to Measure Conformational Changes of Transglutaminase Type 2 in Live Cells. <i>PLoS ONE</i> , 2012, 7, e44159.	2.5	66
49	Dramatic increase of quench efficiency in spacerless dimaleimide fluorogens. <i>Organic and Biomolecular Chemistry</i> , 2011, 9, 185-197.	2.8	27
50	Plasma Membrane Factor XIIIa Transglutaminase Activity Regulates Osteoblast Matrix Secretion and Deposition by Affecting Microtubule Dynamics. <i>PLoS ONE</i> , 2011, 6, e15893.	2.5	52
51	Cytosolic Guanine Nucleotide Binding Deficient Form of Transglutaminase 2 (R580a) Potentiates Cell Death in Oxygen Glucose Deprivation. <i>PLoS ONE</i> , 2011, 6, e16665.	2.5	36
52	Irreversible Inhibitors of Tissue Transglutaminase. <i>Advances in Enzymology and Related Areas of Molecular Biology</i> , 2011, 78, 415-447.	1.3	13
53	Inhibition of Aminoglycoside-Deactivating Enzymes APH(3)-IIIa and AAC(6)-IIi by Amphiphilic Paromomycin O ₂ -Ether Analogues. <i>ChemMedChem</i> , 2011, 6, 1961-1966.	3.2	32
54	Inside Cover: Inhibition of Aminoglycoside-Deactivating Enzymes APH(3)-IIIa and AAC(6)-IIi by Amphiphilic Paromomycin O ₂ -Ether Analogues (ChemMedChem 11/2011). <i>ChemMedChem</i> , 2011, 6, 1942-1942.	3.2	0

#	ARTICLE	IF	CITATIONS
55	Fluorescent Probes of Tissue Transglutaminase Reveal Its Association with Arterial Stiffening. <i>Chemistry and Biology</i> , 2010, 17, 1143-1150.	6.0	22
56	De novo helical peptides as target sequences for a specific, fluorogenic protein labelling strategy. <i>Molecular BioSystems</i> , 2010, 6, 976.	2.9	31
57	Fluorometric assay for tissue transglutaminase-mediated transamidation activity. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 6354-6359.	3.0	13
58	The Crystal Structure of ATP-bound Phosphofructokinase from <i>Trypanosoma brucei</i> Reveals Conformational Transitions Different from those of Other Phosphofructokinases. <i>Journal of Molecular Biology</i> , 2009, 385, 1519-1533.	4.2	38
59	Photolabeling of Tissue Transglutaminase Reveals the Binding Mode of Potent Cinnamoyl Inhibitors. <i>Biochemistry</i> , 2009, 48, 3346-3353.	2.5	23
60	Reversible and Competitive Cinnamoyl Triazole Inhibitors of Tissue Transglutaminase. <i>Chemical Biology and Drug Design</i> , 2008, 72, 189-196.	3.2	60
61	The bioorganic chemistry of transglutaminase " from mechanism to inhibition and engineering. <i>Canadian Journal of Chemistry</i> , 2008, 86, 271-276.	1.1	39
62	Cinnamoyl Inhibitors of Tissue Transglutaminase. <i>Journal of Organic Chemistry</i> , 2008, 73, 5766-5775.	3.2	85
63	The First Crystal Structure of Phosphofructokinase from a Eukaryote: <i>Trypanosoma brucei</i> . <i>Journal of Molecular Biology</i> , 2007, 366, 1185-1198.	4.2	27
64	Convergent Preparation and Photophysical Characterization of Dimaleimide Dansyl Fluorogens: Elucidation of the Maleimide Fluorescence Quenching Mechanism. <i>Journal of the American Chemical Society</i> , 2007, 129, 11969-11977.	13.7	160
65	Acyl transfer from carboxylate, carbonate, and thiocarbonate esters to enzymatic and nonenzymatic thiolates. <i>Canadian Journal of Chemistry</i> , 2007, 85, 164-174.	1.1	11
66	Synthesis and evaluation of peptidic maleimides as transglutaminase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 305-308.	2.2	31
67	6-Hydroxy to 6'-amino tethered ring-to-ring macrocyclic aminoglycosides as probes for APH(3)-IIIa kinase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 3221-3225.	2.2	14
68	β -Glutamyl transpeptidase acylation with peptidic substrates: free energy relationships measured by an HPLC kinetic assay. <i>Organic and Biomolecular Chemistry</i> , 2006, 4, 3790-3801.	2.8	10
69	Synthesis and evaluation of peptidic irreversible inhibitors of tissue transglutaminase. <i>Bioorganic and Medicinal Chemistry</i> , 2006, 14, 8379-8385.	3.0	32
70	Transesterification of trialkyl phosphates from alkyl bromides. <i>Tetrahedron Letters</i> , 2005, 46, 3565-3567.	1.4	7
71	A direct fluorometric assay for tissue transglutaminase. <i>Analytical Biochemistry</i> , 2005, 347, 221-226.	2.4	28
72	Tissue Transglutaminase Inhibition. <i>Chemistry and Biology</i> , 2005, 12, 410-412.	6.0	9

#	ARTICLE	IF	CITATIONS
73	Synthesis and Characterization of Dimaleimide Fluorogens Designed for Specific Labeling of Proteins. <i>Journal of the American Chemical Society</i> , 2005, 127, 559-566.	13.7	142
74	Gamma- ϵ -Glutamyl Transpeptidase Substrate Specificity and Catalytic Mechanism. <i>Methods in Enzymology</i> , 2005, 401, 449-467.	1.0	71
75	Tissue transglutaminase acylation: Proposed role of conserved active site Tyr and Trp residues revealed by molecular modeling of peptide substrate binding. <i>Protein Science</i> , 2004, 13, 979-991.	7.6	37
76	Synthesis of S-alkyl L-homocysteine analogues of glutathione and their kinetic studies with $\hat{\text{I}}^3$ -glutamyl transpeptidase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 3451-3455.	2.2	16
77	Probing the stereochemistry of the active site of gamma-glutamyl transpeptidase using sulfur derivatives of L-glutamic acid. <i>Organic and Biomolecular Chemistry</i> , 2004, 2, 238.	2.8	27
78	Expression and rapid purification of highly active hexahistidine-tagged guinea pig liver transglutaminase. <i>Protein Expression and Purification</i> , 2004, 33, 256-264.	1.3	23
79	Synthesis of aza and oxaglutamyl-p-nitroanilide derivatives and Their kinetic studies with $\hat{\text{I}}^3$ -Glutamyltranspeptidase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2003, 13, 997-1000.	2.2	12
80	Expression, purification, crystallization and preliminary crystallographic analysis of <i>Trypanosoma brucei</i> phosphofructokinase. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2003, 59, 532-534.	2.5	5
81	Synthesis of dipeptide-bound epoxides and $\hat{\text{I}}^{\pm}, \hat{\text{I}}^2$ -unsaturated amides as potential irreversible transglutaminase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2002, 10, 355-360.	3.0	49
82	Mapping of the active site of rat kidney $\hat{\text{I}}^3$ -glutamyl transpeptidase using activated esters and their amide derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2002, 10, 4185-4191.	3.0	16
83	Peptide coupling of unprotected amino acids through in situ p-nitrophenyl ester formation. <i>Tetrahedron Letters</i> , 2002, 43, 7717-7719.	1.4	31
84	Kinetic Studies of Guinea Pig Liver Transglutaminase Reveal a General-Base-Catalyzed Deacylation Mechanism. <i>Biochemistry</i> , 2001, 40, 8335-8342.	2.5	59
85	Evaluation of novel dipeptide-bound $\hat{\text{I}}^{\pm}, \hat{\text{I}}^2$ -unsaturated amides and epoxides as irreversible inhibitors of guinea pig liver transglutaminase. <i>Bioorganic and Medicinal Chemistry</i> , 2001, 9, 1923-1928.	3.0	59
86	Synthesis and evaluation of novel dipeptide-bound 1,2,4-Thiadiazoles as irreversible inhibitors of guinea pig liver transglutaminase. <i>Bioorganic and Medicinal Chemistry</i> , 2001, 9, 3231-3241.	3.0	61
87	A Direct Continuous Spectrophotometric Assay for Transglutaminase Activity. <i>Analytical Biochemistry</i> , 2000, 285, 16-20.	2.4	39
88	A Continuous Spectrophotometric Linked Enzyme Assay for Transglutaminase Activity. <i>Analytical Biochemistry</i> , 1999, 274, 141-144.	2.4	57
89	Guinea Pig Liver Transglutaminase: A Modified Purification Procedure Affording Enzyme with Superior Activity in Greater Yield. <i>Protein Expression and Purification</i> , 1999, 17, 89-95.	1.3	24
90	Controlled Regioselective Anilide Formation from Aspartic and Glutamic Acid Anhydrides. <i>Journal of Organic Chemistry</i> , 1997, 62, 8821-8825.	3.2	28

#	ARTICLE	IF	CITATIONS
91	A Mild and Efficient Modified Hofmann Rearrangement. <i>Journal of Organic Chemistry</i> , 1997, 62, 7495-7496.	3.2	62
92	Preparation of methyl carbamates via a modified Hofmann rearrangement. <i>Tetrahedron Letters</i> , 1997, 38, 313-316.	1.4	45